Locations:
SearchAdvertisement
Study measures real-world outcomes for relapsed or refractory large B-cell lymphoma
Optimized responses in transplant- and CAR T-cell therapy-eligible patients
Findings from large database important to inform clinical practice
Socioeconomic disparities have a notable influence on access to allogeneic hematopoietic cell transplant
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
What’s coming up at ASH and beyond
Blinatumomab plus chemotherapy improves overall survival and relapse-free survival over chemotherapy alone
First-ever U.S. population-level retrospective analysis reveals many patients with systemic mastocytosis need faster intervention
Global R&D efforts expanding first-line and relapse therapy options for patients
A case study on the value of access to novel therapies through clinical trials
Multiple Cleveland Clinic sites to participate in National Cancer Institute trial comparing treatment regimens for newly diagnosed patients
Advertisement
Advertisement